From : **LSCP** Global Management Team
To : Global Customers & Friends
Subject : Cynthia J. Davenport, Ph.D. joins LSCP – for immediate release

---

Uerikon/Zurich, Switzerland, July 23, 2010 - Today the **LSCP** Life Sciences Consulting Partners Management Team takes great pleasure in announcing that

Ms. Cynthia J. Davenport

Ph.D., Experimental Pathology University of California at Los Angeles (UCLA) Medical School
M.S., Physiology Louisiana State University, Baton Rouge, LA
B.S., Biology Millsaps College, Jackson, MS. Magna Cum Laude. Secondary emphasis: BAdmin.
Postdoctoral Fellowships:
Neurology Stanford University Medical School Palo Alto, CA
Toxicology Chemical Industry Institute of Toxicology (CIIT) Centers for Health Research, Research Triangle Park, NC (currently named The Hamner Institute)

has formally joined our global **LSCP** network as a Subject Matter Expert (SME).

Before joining, Cynthia's latest professional activities were

- Supplied source documents and addressed queries for multiple global regulatory filings: (Investigational New Drug [IND], New Drug Application [NDA], Marketing Authorization Application [MAA], New Animal Drug Application [NADA], Maximum Residue Limit [MRL], Experimental Testing Permit [ETP], and a companion animal pharmaceutical filing [ATC] in the European Union). Global regulatory queries were minimal and responses were all accepted without further modification
- Mentor to and liaison with senior staff and executive site management for preclinical drug development of two compounds at big pharma in Japan. As a result, 1) the senior staff was able to contribute significantly to drug development team decisions, and 2) the site successfully supported its first two preclinical safety packages for Phase 1 clinical trials. Received a "Succeeding Through People" Achievement Award in recognition of these efforts
- Designed and executed numerous preclinical drug development strategies (Phase 1 to Phase 3), identified development issues, and formulated and presented results to upper management. Compound development was effectively managed and all safety packages were accepted by global regulatory agencies with minimal to no queries
- Designed protocols, conducted, and monitored 170 preclinical safety studies in multiple species. Evaluated and reported integrated safety data. Global regulatory acceptance of quality data with minimal to no queries, including two marketed products: Draxxin® (tulathromycin) and Convenia® (cefovecin)

"The LSCP Global Management Team is very pleased to see Cynthia joining and become an active member of our global group. Not only her in-depth knowledge of industry business processes from pre-clinical research to eIND, but also her acquired expertise in the context of our eCTD Product Information (PI) ***and Structured Content Authoring*** (SCA & Granularity) ***initiative makes her an excellent addition to the Team!"***

A very hearty welcome to Cynthia!

For a personal/group contact or full CV:
cynthia.davenport@lsconsultingpartners.com or ruedi.blattmann@lsconsultingpartners.com
www.lsconsultingparterns.com

LSCP ◆ 11 Fangenstrasse, CH-8713 Uerikon/Zurich, Switzerland
Phone: +41 (0) 44 784 69 72, Mobile: +41 79 745 13 63